Rocket Pharmaceuticals (RCKT) executive compensation, 2026 proxy

Gaurav D. Shah, M.D., Chief Executive Officer, was paid $3.5M in 2025, down 49% from $6.8M the year before.

Filed
April 6, 2026
Annual meeting
May 20, 2026
Pay year
2025
Named executives
3
CEO total pay
$3.5M-49% vs prior year
CEO pay in equity
69%$2.4M in awards
Prior say-on-pay support
98%of votes cast
CEO Total Compensation
$3,510,241For fiscal 2025
COO Sign-on Bonus
$125,000Paid to Christopher Stevens

How M.D. was paid

$3.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary19%Stock awards23%Option awards46%Non-equity incentive11%All other compensation0%

Named executive officers

ExecutiveTotal
Gaurav D. Shah, M.D.Chief Executive Officer$3,510,241
Christopher StevensChief Operating Officer$3,555,467
Martin WilsonGeneral Counsel and Chief Corporate Officer, Senior Vice President, Interim Principal Financial Officer$3,397,880

What changed and why

  • $3.5MGaurav D. Shah received total compensation of $3,510,241 in fiscal 2025, a decrease from $6,841,407 in fiscal 2024.
  • $125KChristopher Stevens was hired as Chief Operating Officer in July 2025 with a sign-on bonus of $125,000.
  • Martin Wilson was appointed interim Principal Financial Officer on September 8, 2025.
  • 98%The 2025 say-on-pay proposal was approved by approximately 98 percent of the votes cast.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.